Vorarlberger Krankenhaus-Betriebsgesellschaft mbH
- Address
- lock Available on a paid plan
Cardiovascular Diseases
At Vorarlberger Krankenhaus-Betriebsgesellschaft mbH in Feldkirch, clinical research in cardiovascular disease focuses on people with atherosclerotic cardiovascular disease and elevated lipoprotein(a). These studies are designed to assess whether a new treatment approach can reduce major heart-related events and improve protection against future complications.
- Evaluating a therapy aimed at lowering the risk of coronary heart disease death, myocardial infarction, and urgent revascularization
- Studying patients with ASCVD and elevated Lp(a) to better understand treatment benefit in high-risk heart disease
The work in this area reflects a strong focus on prevention, risk reduction, and improving outcomes for patients with advanced cardiovascular conditions.
Neoplasms
The oncology research at this hospital addresses non-small cell lung cancer, especially c-Met overexpressing, EGFR wildtype, non-squamous disease. The trials are testing whether a targeted treatment can offer better disease control than standard care for adults whose cancer has already been treated.
- Assessing a new targeted cancer therapy for previously treated non-squamous NSCLC
- Comparing treatment effectiveness in patients with c-Met high overexpressing and broader c-Met overexpressing tumor groups
This research is centered on improving survival and disease management in a difficult-to-treat form of lung cancer.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 11 therapeutic areas and 15 of 100 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 100 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 13 by active trials.
- 1Amgen Inc.4active
lock +12 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Amgen Inc.8trials
lock +6 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 152 other sites in Austria
Therapeutic Area Benchmark — Austria
Select a therapeutic area to compare against other sites in Austria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Austria
Market Share
Country: Austria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Vorarlberger Krankenhaus-Betriebsgesellschaft mbH
lock Showing 1 of 42 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A multicenter, randomized open-label study to assess the efficacy, safety, and pharmacokinetics of upadacitinib with a tocilizumab reference arm in subjects from 1 year to less than 18 years old with active systemic juvenile idiopathic arthritis. | AbbVie Deutschland GmbH & Co. KG | Phase III | Recruiting | Mar 2024 | — |
IMP list
lock Showing 1 of 100 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 7 | Unknown | 2023-11-01 | 2026-06-11 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.